Almonty's $129 Million War Chest Meets a More Cautious Analyst Scorecard
Published on 11/04/2026 at 06:51 | Editorial boerse-global.de
Almonty has just banked US$129,375,000 in gross proceeds from a share sale — and watched two analysts cut their price targets within a week of each other. Neither development cancels the other out. Together they frame the real question hanging over the tungsten miner: whether the money and the Sangdong ramp-up can be converted into per-share value on a timetable the market will accept.
The Raise, in Plain Numbers
The company sold 20,700,000 common shares at US$6.25 apiece, a figure that includes the underwriters' over-allotment option exercised in full. Gross proceeds came to US$129,375,000.
That "gross" qualifier matters, and so does the structure. The cash arrives through newly issued stock, which means a bigger balance sheet sits alongside a larger share count. A completed placement, on its own, says nothing about value per share — it only sets the stage.
Management has earmarked the funds for exploration and project development, mine expansion, and working capital and general corporate purposes. That is a wide brief. Investors would be wrong to read it as operating results already in hand.
Should investors sell immediately? Or is it worth buying Almonty?
Two Targets, One Message
Stifel moved first, on 20 October, trimming its target to $21 from $25 while keeping its buy rating. The trigger was fresh guidance on delivery timing for Sangdong's first and second phases, presented at the company's investor day. The analysts pushed their delivery assumptions back in their valuation model accordingly.
B. Riley Securities followed on 27 October, with analyst Nick Giles cutting his target to $20 from $25 and likewise sticking with a buy. That adjustment reflected the anticipated production ramp-up at Sangdong.
Read side by side, the two notes point the same way. Neither house abandoned its constructive stance on Almonty; both simply marked their valuations lower. A trimmed target is not a sell signal — nor is a buy rating an all-clear on operational execution.
A Paid Report, and Why the Label Matters
How conditional the valuation case remains is underlined by a sponsored research note dated 21 October. It put an illustrative value of US$20.00 per share on the stock — explicitly contingent on successful execution.
The provider also disclosed that Almonty had paid it up to US$100,000 for sponsored research services through that date. That payment belongs in the frame: the document is commissioned analysis and should not be read outside that context.
Almonty at a turning point? This analysis reveals what investors need to know now.
The takeaway for investors is a clean split between valuation and proof. Buy ratings and modelled share prices express expectations. They do not certify that the assumed production and delivery schedule has been met.
What Actually Settles the Argument
The common thread running through every assessment is execution at Sangdong. The question is whether Almonty can deliver on its ramp-up expectations — and that is precisely what both the softer targets and the explicitly conditional valuation hinge on.
Capital creates room to manoeuvre; it does not substitute for economic success. The placement is done, the stated uses of proceeds describe intentions, and the lowered targets are analyst opinions rather than a fixed corporate value. The yardstick is not whether Almonty could close a large financing, but what the company does with the headroom it now has.
Ad
Almonty Stock: New Analysis - 4 November
Fresh Almonty information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
